KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Equity Average (2016 - 2026)

Abbott Laboratories' Equity Average history spans 18 years, with the latest figure at $52.4 billion for Q1 2026.

  • On a quarterly basis, Equity Average rose 118.74% to $52.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $52.4 billion, a 118.74% increase, with the full-year FY2025 number at $26.5 billion, up 21007.97% from a year prior.
  • Equity Average hit $52.4 billion in Q1 2026 for Abbott Laboratories, up from $52.0 billion in the prior quarter.
  • Over the last five years, Equity Average for ABT hit a ceiling of $52.4 billion in Q1 2026 and a floor of -$11.6 billion in Q3 2022.
  • Historically, Equity Average has averaged $13.8 billion across 5 years, with a median of $5.1 billion in 2022.
  • Biggest five-year swings in Equity Average: crashed 363.92% in 2022 and later skyrocketed 75453.79% in 2025.
  • Tracing ABT's Equity Average over 5 years: stood at $5.1 billion in 2022, then tumbled by 183.11% to -$4.2 billion in 2023, then soared by 102.2% to $93.0 million in 2024, then skyrocketed by 55832.8% to $52.0 billion in 2025, then grew by 0.77% to $52.4 billion in 2026.
  • Business Quant data shows Equity Average for ABT at $52.4 billion in Q1 2026, $52.0 billion in Q4 2025, and $49.9 billion in Q3 2025.